Patients with severe COVID-19 pneumonia often need to be mechanically intubated and have an increased mortality risk. Tocilizumab, a drug used against the cytokine storm underlying this clinical condition, has shown positive effects in clinical trials.
Interview with Professor Cristina Mussini, Head of the Department of Infectious Diseases and Tropical Medicine at the University of Modena and Reggio Emilia in Italy and member of the European AIDS Clinical Society. She has been actively involved in various recent studies on the clinical use of tocilizumab in patients with COVID-19 pneumonia. First a ...
Interview with Dr Andrew Ip, a specialist in hematology/oncology at the John Theurer Cancer Center at Hackensack University Medical Center, USA, who has been involved in research on tocilizumab use in COVID-19 patients. Why did you choose tocilizumab to treat patients with COVID-19 pneumonia? Andrew Ip: Tocilizumab is a monoclonal antibody that inhibits the interleukin-6 ...
Interview with Dr Juan Victor San-Martín López, a physician specialising in infectious diseases and a member of the task force coordinating responses to the leishmaniasis outbreak in 2011 and to COVID-19 at the Hospital Universitario de Fuenlabrada, Spain. He reports on his experience with tocilizumab use in COVID-19 patients. What is the so-called cytokine storm? ...
A few weeks after the SARS-CoV-2 was identified by Chinese researchers as the cause of ‘COVID-19’, an antiviral called remdesivir, originally used during the 2014 Ebola outbreak, came into play as the first available option to treat patients with coronavirus disease 2019 (COVID-19). Even if the approval process for remdesivir caused some controversy, experts consider the combined use of antivirals and other drugs a promising solution for treatment of Covid-19.
Interview with Martijn van Hemert, Associate professor and Principal Investigator in molecular virology and antiviral strategies at the Leiden University Medical Center. In recent years, his group has mainly been studying the Chikungunya and Zika viruses, but in the past he has also studied SARS-CoV. Since February 2020, he has shifted his focus to research ...
Interview with Juan Pablo Horcajada, MD. is Head of the Department of Infectious Diseases and General Coordinator of the COVID-19 Service at the Hospital del Mar, Barcelona. Remdesivir is the first drug approved by the EMA to be used as part of the treatment of COVID-19 patients. How’s the use of this antiviral in your ...
Clinical trials make it possible to evaluate whether a treatment improves outcomes. Developing a hypothesis, for example if treatment A is better than standard treatment B, clinical trials enable understanding of the role of an intervention in improving patient care. In the current search for a successful treatment against COVID-19, ongoing multiple clinical trials have started to make a difference, such as the Recovery clinical trial on dexamethasone, which has given a definitive verdict on the use of corticosteroids during COVID-19.
onAugust 26, 2020
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. This also includes all cookies allowing the proper functioning of the website under Wordpress.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses AT Internet to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!